Award

NHS England procurement for the supply of Hepatitis C treatments and the provision of Hepatitis C elimination initiatives

NHS ENGLAND

This public procurement record has 1 release in its history.

AwardUpdate

13 Mar 2024 at 14:38

Summary of the contracting process

The National Health Service (NHS) England initiated a tender for the supply of Hepatitis C treatments and related elimination initiatives. The procurement, managed by the NHS Arden & Greater East Midlands Commissioning Support Unit on behalf of NHS England Specialised Commissioning, aims to accelerate the elimination of Hepatitis C in England by providing treatments and services. The initial contract period runs from May 1, 2019, to March 31, 2024, with a possible extension. Gilead Sciences Limited is the active supplier for this contract, valued at £1.2 billion.

This NHS England tender offers opportunities for businesses involved in pharmaceutical products and healthcare services. The contract requires suppliers to have Direct Acting Antivirals (DAAs) for Hepatitis C treatment. Companies providing such products can benefit from participating in this procurement to expand their market reach and contribute to the national health objectives. Being part of this initiative aligns with businesses focused on pharmaceuticals, healthcare services, and public health solutions.

Find more tenders on our Open Data Platform.
How relevant is this notice?

D3 Tenders Premium

Win More Public Sector Contracts

AI-powered tender discovery, pipeline management, and market intelligence — everything you need to grow your public sector business.

Notice Title

NHS England procurement for the supply of Hepatitis C treatments and the provision of Hepatitis C elimination initiatives

Notice Description

Lot Information

Lot 1

This procurement will be conducted by NHS Arden & Greater East Midlands Commissioning Support Unit on behalf of NHS England Specialised Commissioning.
Contract(s) entered into pursuant to this procurement will be between the successful supplier(s) and NHS England (National Health Service Commissioning Board).
Organisations wishing to participate in the procurement must have at least one Direct Acting Antiviral (DAA) for the treatment of Hepatitis C within their product portfolio. There is no restriction on the number of DAA products that bidders can offer for, or that can be included in the contract(s).
Contract(s) awarded pursuant the procurement exercise are for use by the Department of Health, Public Health England, the NHS in England; and be used by private sector contractors and agents working on behalf of the aforementioned
Appointed suppliers will be responsible for (i) the supply of Hepatitis C DAA treatments and (ii) the provision of Hepatitis C elimination initiatives and/or services to help identify and treat Hepatitis C patients so as to accelerate the elimination of Hepatitis C in England from 1st October 2018. The duration of any Contract(s) awarded will be for an initial period of three (3) years, with an option to extend (at the sole discretion of the contracting authority) for an additional period or periods up to two (2) years.
Further information, including details regarding the Lots, is set out in the procurement documents which are available to download (see below for details)
The contracting authority intends to use the NHS Arden & Greater East Midlands Commissioning Support Unit e-procurement portal in this procurement exercise.
i) To Register - log onto the portal at https://ardengemcsu.bravosolution.co.uk (registration and use of the website is free of charge).
ii) Express interest by:
a) selecting response to advert and PQQ (ref: pqq_483) and ITT (ref: itt_958)
b) select Open Access ITT
c) search for and access listing related to this contract and view details
d) click on Express Interest link
iii) Once you have expressed interest, access the My ITTs page where you can download and complete the ITT.

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-04482a
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/008048-2024
Current Stage
Award
All Stages
Award

Procurement Classification

Notice Type
Award Notice
Procurement Type
Standard
Procurement Category
Goods
Procurement Method
Not Specified
Procurement Method Details
Not specified
Tender Suitability
Not specified
Awardee Scale
Large

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products


CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
Not specified
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
£1,200,000,000 £1B-£10B

Notice Dates

Publication Date
13 Mar 20241 years ago
Submission Deadline
Not specified
Future Notice Date
Not specified
Award Date
30 Apr 20196 years ago
Contract Period
30 Apr 2019 - 31 Mar 2024 4-5 years
Recurrence
Not specified

Notice Status

Tender Status
Not Specified
Lots Status
Not Specified
Awards Status
Active
Contracts Status
Active

Contracting Authority (Buyer)

Main Buyer
NHS ENGLAND
Contact Name
Mark Perkins
Contact Email
mark.perkins@nhs.net
Contact Phone
Not specified

Buyer Location

Locality
LEEDS
Postcode
LS2 7UE
Post Town
Leeds
Country
England

Major Region (ITL 1)
TLE Yorkshire and The Humber
Basic Region (ITL 2)
TLE4 West Yorkshire
Small Region (ITL 3)
TLE42 Leeds
Delivery Location
Not specified

Local Authority
Leeds
Electoral Ward
Little London & Woodhouse
Westminster Constituency
Leeds Central and Headingley

Supplier Information

Number of Suppliers
1
Supplier Name

GILEAD SCIENCES

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

Download

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-h6vhtk-04482a-2024-03-13T14:38:44Z",
    "date": "2024-03-13T14:38:44Z",
    "ocid": "ocds-h6vhtk-04482a",
    "initiationType": "tender",
    "tender": {
        "id": "ocds-h6vhtk-04482a",
        "legalBasis": {
            "id": "32014L0024",
            "scheme": "CELEX"
        },
        "title": "NHS England procurement for the supply of Hepatitis C treatments and the provision of Hepatitis C elimination initiatives",
        "classification": {
            "scheme": "CPV",
            "id": "33600000",
            "description": "Pharmaceutical products"
        },
        "mainProcurementCategory": "goods",
        "lots": [
            {
                "id": "1",
                "description": "This procurement will be conducted by NHS Arden & Greater East Midlands Commissioning Support Unit on behalf of NHS England Specialised Commissioning.<br/>Contract(s) entered into pursuant to this procurement will be between the successful supplier(s) and NHS England (National Health Service Commissioning Board).<br/>Organisations wishing to participate in the procurement must have at least one Direct Acting Antiviral (DAA) for the treatment of Hepatitis C within their product portfolio. There is no restriction on the number of DAA products that bidders can offer for, or that can be included in the contract(s).<br/>Contract(s) awarded pursuant the procurement exercise are for use by the Department of Health, Public Health England, the NHS in England; and be used by private sector contractors and agents working on behalf of the aforementioned<br/>Appointed suppliers will be responsible for (i) the supply of Hepatitis C DAA treatments and (ii) the provision of Hepatitis C elimination initiatives and/or services to help identify and treat Hepatitis C patients so as to accelerate the elimination of Hepatitis C in England from 1st October 2018. The duration of any Contract(s) awarded will be for an initial period of three (3) years, with an option to extend (at the sole discretion of the contracting authority) for an additional period or periods up to two (2) years.<br/>Further information, including details regarding the Lots, is set out in the procurement documents which are available to download (see below for details)<br/>The contracting authority intends to use the NHS Arden & Greater East Midlands Commissioning Support Unit e-procurement portal in this procurement exercise.<br/>i) To Register - log onto the portal at https://ardengemcsu.bravosolution.co.uk (registration and use of the website is free of charge).<br/>ii) Express interest by:<br/>a) selecting response to advert and PQQ (ref: pqq_483) and ITT (ref: itt_958)<br/>b) select Open Access ITT<br/>c) search for and access listing related to this contract and view details<br/>d) click on Express Interest link<br/>iii) Once you have expressed interest, access the My ITTs page where you can download and complete the ITT.",
                "contractPeriod": {
                    "startDate": "2019-05-01T00:00:00+01:00",
                    "endDate": "2024-03-31T23:59:59+01:00"
                }
            }
        ],
        "items": [
            {
                "id": "1",
                "deliveryAddresses": [
                    {
                        "region": "UK"
                    }
                ],
                "relatedLot": "1"
            }
        ],
        "techniques": {
            "frameworkAgreement": {
                "periodRationale": "The original advertised aim of the contract was to eliminate Hepatitis C in England. This has nearly been achieved but further services and/or supplies are necessary to achieve the elimination targets, as the last groups are harder to reach. It would not be possible to change contractor(s) for technical reasons at this stage of the programme (and no-one else can supply these medicines) and/or to do so would cause substantial inconvenience and duplication of costs.<br/>It was not foreseen that it would take longer than anticipated to get to the hard to reach groups or that the programme would be delayed due to Covid-19. <br/>The modification (i.e. extension) does not alter the overall nature of the contract as (a) the overall aim has not changed; and (b) the Authority are simply requiring more of the same supplies and services for a further two years. <br/>The increase in costs of the modification does not exceed 50% of the original contract value."
            }
        }
    },
    "awards": [
        {
            "id": "008048-2024-01/05/2019-31/03/2024-1",
            "relatedLots": [
                "1"
            ],
            "title": "NHS England procurement for the supply of Hepatitis C treatments and the provision of Hepatitis C elimination initiatives",
            "status": "active",
            "suppliers": [
                {
                    "id": "GB-FTS-107729",
                    "name": "Gilead Sciences Limited"
                }
            ]
        }
    ],
    "parties": [
        {
            "id": "GB-FTS-3022",
            "name": "NHS England",
            "identifier": {
                "legalName": "NHS England"
            },
            "address": {
                "streetAddress": "Quarry House, Quarry Hill",
                "locality": "Leeds",
                "region": "UK",
                "postalCode": "LS2 7UE",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "name": "Mark Perkins",
                "email": "mark.perkins@nhs.net"
            },
            "roles": [
                "buyer",
                "mediationBody"
            ],
            "details": {
                "url": "https://www.england.nhs.uk/",
                "buyerProfile": "https://www.england.nhs.uk/"
            }
        },
        {
            "id": "GB-FTS-107729",
            "name": "Gilead Sciences Limited",
            "identifier": {
                "legalName": "Gilead Sciences Limited",
                "id": "02543818"
            },
            "address": {
                "streetAddress": "280 High Holborn, London",
                "locality": "London",
                "region": "UK",
                "postalCode": "WC1V 7EE",
                "countryName": "United Kingdom"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "url": "http://www.gilead.com",
                "scale": "large"
            }
        },
        {
            "id": "GB-FTS-1661",
            "name": "The High Court",
            "identifier": {
                "legalName": "The High Court"
            },
            "address": {
                "streetAddress": "The Strand",
                "locality": "London",
                "postalCode": "WC2A 2LL",
                "countryName": "United Kingdom"
            },
            "roles": [
                "reviewBody"
            ],
            "details": {
                "url": "https://www.judiciary.uk/courts-and-tribunals/high-court/"
            }
        }
    ],
    "buyer": {
        "id": "GB-FTS-3022",
        "name": "NHS England"
    },
    "contracts": [
        {
            "id": "008048-2024-01/05/2019-31/03/2024-1",
            "awardID": "008048-2024-01/05/2019-31/03/2024-1",
            "title": "NHS England procurement for the supply of Hepatitis C treatments and the provision of Hepatitis C elimination initiatives",
            "status": "active",
            "value": {
                "amount": 1200000000,
                "currency": "GBP"
            },
            "dateSigned": "2019-05-01T00:00:00+01:00",
            "period": {
                "startDate": "2019-05-01T00:00:00+01:00",
                "endDate": "2024-03-31T23:59:59+01:00"
            },
            "periodRationale": "The original advertised aim of the contract was to eliminate Hepatitis C in England. This has nearly been achieved but further services and/or supplies are necessary to achieve the elimination targets, as the last groups are harder to reach. It would not be possible to change contractor(s) for technical reasons at this stage of the programme (and no-one else can supply these medicines) and/or to d",
            "items": [
                {
                    "id": "1",
                    "classification": {
                        "scheme": "CPV",
                        "id": "33600000",
                        "description": "Pharmaceutical products"
                    },
                    "deliveryAddresses": [
                        {
                            "region": "UK"
                        }
                    ],
                    "relatedLot": "1"
                }
            ],
            "amendments": [
                {
                    "id": "1",
                    "description": "Nature and extent of the modifications (with indication of possible earlier changes to the contract):<br/>The contract is to be extended for a further two years. No further modifications are to be made except for the extension in duration [(save that Vosevi shall be added as a Supplier's Treatment but shall not be included when calculating the Supplier's actual market share or Recommended Market Share).]",
                    "rationale": "Need for additional works, services or supplies by the original contractor/concessionaire: The original advertised aim of the contract was to eliminate Hepatitis C in England. This has nearly been achieved but further services and/or supplies are necessary to achieve the elimination targets, as the last groups are harder to reach. It would not be possible to change contractor(s) for technical reasons at this stage of the programme (and no-one else can supply these medicines) and/or to do so would cause substantial inconvenience and duplication of costs.<br/>It was not foreseen that it would take longer than anticipated to get to the hard to reach groups or that the programme would be delayed due to Covid-19. <br/>The modification (i.e. extension) does not alter the overall nature of the contract as (a) the overall aim has not changed; and (b) the Authority are simply requiring more of the same supplies and services for a further two years. <br/>The increase in costs of the modification does not exceed 50% of the original contract value."
                }
            ]
        }
    ],
    "language": "en"
}